Update on corticosteroids for diabetic macular edema

Stephen Schwartz, Ingrid U. Scott, Michael W. Stewart, Harry W Flynn

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME.

Original languageEnglish (US)
Pages (from-to)1723-1730
Number of pages8
JournalClinical Ophthalmology
Volume10
DOIs
StatePublished - Sep 8 2016

Fingerprint

Macular Edema
Adrenal Cortex Hormones
Vascular Endothelial Growth Factor A
Fluocinolone Acetonide
Triamcinolone Acetonide
Endophthalmitis
Intraocular Pressure
Cataract
Dexamethasone
Therapeutics
Injections

Keywords

  • Dexamethasone
  • Diabetic macular edema
  • Fluocinolone acetonide
  • Randomized clinical trial
  • Triamcinolone acetonide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Update on corticosteroids for diabetic macular edema. / Schwartz, Stephen; Scott, Ingrid U.; Stewart, Michael W.; Flynn, Harry W.

In: Clinical Ophthalmology, Vol. 10, 08.09.2016, p. 1723-1730.

Research output: Contribution to journalReview article

Schwartz, Stephen ; Scott, Ingrid U. ; Stewart, Michael W. ; Flynn, Harry W. / Update on corticosteroids for diabetic macular edema. In: Clinical Ophthalmology. 2016 ; Vol. 10. pp. 1723-1730.
@article{563a6d35709c4882bfcb93a1c2fb1f13,
title = "Update on corticosteroids for diabetic macular edema",
abstract = "Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME.",
keywords = "Dexamethasone, Diabetic macular edema, Fluocinolone acetonide, Randomized clinical trial, Triamcinolone acetonide, Vascular endothelial growth factor",
author = "Stephen Schwartz and Scott, {Ingrid U.} and Stewart, {Michael W.} and Flynn, {Harry W}",
year = "2016",
month = "9",
day = "8",
doi = "10.2147/OPTH.S115546",
language = "English (US)",
volume = "10",
pages = "1723--1730",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Update on corticosteroids for diabetic macular edema

AU - Schwartz, Stephen

AU - Scott, Ingrid U.

AU - Stewart, Michael W.

AU - Flynn, Harry W

PY - 2016/9/8

Y1 - 2016/9/8

N2 - Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME.

AB - Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wishing to reduce the number of required injections, and in pregnant patients. Intravitreal triamcinolone acetonide has been used for many years but is not approved for this indication. An extended-release bioerodable dexamethasone delivery system and an extended-release nonbioerodable fluocinolone acetonide insert have both achieved regulatory approval for the treatment of DME. All intravitreal corticosteroids are associated with risks of cataract progression, elevation of intraocular pressure, and endophthalmitis. There is no current consensus regarding the use of corticosteroids, but they are valuable for selected patients with center-involving DME.

KW - Dexamethasone

KW - Diabetic macular edema

KW - Fluocinolone acetonide

KW - Randomized clinical trial

KW - Triamcinolone acetonide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84988857206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988857206&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S115546

DO - 10.2147/OPTH.S115546

M3 - Review article

AN - SCOPUS:84988857206

VL - 10

SP - 1723

EP - 1730

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -